Inmagene’s anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study
Article Date
August 18, 2023
This article is featured on another website.
Go to article
August 17, 2023
Chime Biologics Relisted in the Hurun Future Unicorns in the World 2023, Recognized by the Market for Growth
August 17, 2023
Chime Biologics Relisted in the Hurun Future Unicorns in the World 2023, Recognized by the Market for Growth
September 19, 2023
Chime Biologics Announced Global Strategic Cooperation with Panolos Bioscience to Advance Multi-specific Therapeutic Proteins Development
September 19, 2023